bluebird bio Inc Temporary Suspension On Phase 1/2 And Phase 3 Studies Of LentiGlobin Gene Therapy For Sickle Cell Disease (bb1111) Corporate Call Transcript
Ladies and gentlemen, thank you for standing by, and welcome to the bluebird bio conference call. (Operator Instructions)
I would now like to turn the conference over to Ms. Ingrid Goldberg, VP of IR. Please go ahead.
Good morning, and thank you for joining today's conference call. Before we begin, I would like to remind everyone that we will make statements of the company's future plans and prospects that constitute forward-looking statements. Actual results may differ materially as a result of various important factors, including those discussed in the company's SEC filings. These forward-looking statements represent our estimates as of today and should not be relied upon as representing our estimates as of any future date. We specifically disclaim any obligation to update forward-looking statements even if our estimates change.
Thank you for joining. I will now turn the call over to Nick.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |